Over the past quarter century we have come to realise that through overprescribing, lack of alternatives and lack of understanding, we've used up much of the bandwidth of our existing array of antibiotics. These weary soldiers in the army of medicines, many of which date back decades, have been diminished in their effectiveness by the natural agility of bacterial pathogens which rapidly evolve and develop resistance. Historically, we have looked in the same places to identify replacements for old, decreasingly effective antibiotics. And to no great surprise, we've mostly come up with dead ends or, at best, minor improvements (with very occasional outliers such as Colistin, reserved as weapons of last resort only). And because the pathogens we are facing will evolve to render any new antibiotics ineffective, new approved treatments will have a limited useful life in which to recover the cost of development.